BioMérieux's BioFire Diagnostics acquisition is already producing financial gains

French diagnostics giant bioMérieux closed its $450 million acquisition of Utah's BioFire Diagnostics only in January, but the investment is already beginning to pay off. Earnings during the quarter hit $512.5 million, 3.3% higher than the same period in 2013. BioFire added $19.3 million in quarterly revenues, the company said, mostly from sales generated by its FilmArray Respiratory and Blood Culture Identification tests. BioMérieux said it enjoyed large sales gains in North America, but sales dropped in the Asia Pacific and Latin American markets. As of the end of the first quarter, bioMérieux's debt came in at $44 million, with $35.3 million in net cash on hand. More

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.